Loading patent…
AssigneeMerrimack Pharmaceuticals, Inc.
InventorsVictor MOYO, Gabriela GARCIA
Estimating the term…
Provided are methods of suppressing growth of triple negative breast tumors and basal-like breast tumors by contacting tumor cells with an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. Also provided are methods for treating triple negative breast cancer or basal-like breast cancer in a patient by administering to the patient an ErbB3 inhibitor, e.g., an anti-ErbB3 antibody. The treatment methods can further comprise selecting a patient having a triple negative breast cancer or basal-like breast cancer and then administering an ErbB3 inhibitor to the patient. The treatment methods also can further comprise administering at least one additional anti-cancer agent to the patient in combination with the ErbB3 inhibitor.
1-23. (canceled)
A method of suppressing growth of triple negative breast cancer cells in a patient having a tumor that is identified as triple negative breast cancer, the method comprising administering to the patient an effective amount of an anti-ErbB3 antibody, or antigen-binding fragment thereof, comprising a VH CDR1 sequence of SEQ ID NO:3, a VH CDR2 sequence of SEQ ID NO:4 and a VH CDR3 sequence of SEQ ID NO:5, and a VL CDR1 sequence of SEQ ID NO:6, a VL CDR2 sequence of SEQ ID NO:7 and a VL CDR3 sequence of SEQ ID NO:8.
A method of suppressing growth of triple negative breast cancer cells in a patient, the method comprising:
Dependencies are inferred from the claim text.